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In the present study, we demonstrated the efficacy of low-dose, long-term therapy with erythromycin and an 
erythromycin-related compound, roxithromycin, in patients with chronic lower respiratory tract disease including diffuse 
panbronchiolitis (DPB), and investigated the anti-inflammatory action of such drugs. Treatment significantly improved 
the mean value of respiratory function tests and arterial blood gas analysis, except for PaC02 in the erythromycin-treated 
group and residual volume/total lung capacity (RVTTLC) and PaC02 in the roxithromycin-treated group. Bronchoalveolar 
lavage (BAL) analysis revealed that neutrophils had accumulated in the pre-treatment lavage fluid, compared with that 
of healthy volunteers, and the levels of neutrophil chemotactic activity (NCA), interleukin-1P (IL-IP), interleukin-8 (11-8) 
and leukotriene B4 (LTB4) in BAL fluid of the patients were significantly higher than those in healthy volunteers. 
Macrolide therapy caused a significant reduction in the percentage of neutrophils, NCA and mean IL-ID, IL-8 and LTB4 
concentration in BAL fluid of the patients. The quantitative expression of Mac-I on peripheral neutrophils significantly 
increased, compared with that in healthy volunteers, before therapy and significantly decreased after therapy. We also 
evaluated the in vitro inhibitory effects of macrolides on 11-8 production by vitamin D3-induced human monocytic cell 
line THP-1 cells when stimulated with lipopolysaccharide and serum. 
The present study has also provided evidence for T-cell activation in BAL fluid of the patients, and a significantly reduced 
number of activated T-cells was observed after macrolide therapy. These results indicate that macrolides may act by 
reducing pulmonary inflammation through reduction of neutrophil accumulation, as a consequence of reduced 
chemotactic gradient and cytokine production at the inflammatory sites in the lung or of reduced neutrophil adhesion 
molecules in the circulation. Ultimately the mechanism may involve suppression of neutrophil oxidative and proteolytic 
products. Lymphocytes are important cellular components of bronchial inflammation, in addition to neutrophils, in this 
disease, and macrolide antibiotics may also act as an immunosuppressant to inhibit T-cell activation. This is believed to 
be one reason why macrolides are effective in chronic lower respiratory tract disease. 
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Diffuse panbronchiolitis (DPB) is a chronic infection of 
the lower respiratory tract, first reported in Japan in 
1969 [l]. Unlike the situation in Western countries, 
where only a few cases have been reported, DPB is 
more common in Japan [2 ,3] .  Isolation of Haemophilus 
injuenzae and Streptococcus pneurnoniae from sputum 
occurs early in the course of DPB and this can change 
to Pseudomonas aeruginosa as the disease progresses. The 
condition progresses insidiously and the prognosis, 
especially after infection with I? aeruginosa, is considered 
poor. 
In 1987, the Research Project Team of the 
Ministry of Health and Welfare for specific diseases in 
Japan found that the 1 0-year survival rate was 12.4% in 
cases infected with I? aeruginosa. However, since several 
Japanese studies demonstrated the therapeutic benefits 
of ‘low-dose and long-term’ erythromycin use (600 
mg/day) in DPB, leading to a significant improvement 
of clinical symptoms; radiologic and laboratory tests, 
this therapy has been reported to increase the 10-year 
survival to more than 90% [4]. 
Erythromycin is a macrolide antibiotic used com- 
monly in patients with respiratory infections. However, 
it is not an effective antibiotic for treating I? aeruginosa 
infection, since the minimum inhibitory concentration 
(MIC) is usually more than 100 pg/ml, and the pro- 
liferation of I? aeruginosa is never inhibited. This led us 
to the possibility that erythromycin could have an anti- 
inflammatory effect rather than being bactericidal in 
patients with chronic infection of the lower respiratory 
tract. In the present study we demonstrated the efficacy 
of low-dose, long-term therapy with erythromycin and 
an erythromycin-related compound, roxithromycin, in 
patients with chronic lower respiratory tract disease 
including DPB, and attempted to investigate any 
additional, anti-inflammatory mechanisms. 
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MATERIALS AND METHODS 
The patient group consisted of 31 with DPB and 4 
with bronchiectasis accompanied by chronic sinusitis. 
All patients received oral erythromycin therapy at 600 
mg/day or roxithromycin therapy at 150 mg/day for at 
least 3 months. None was treated with corticosteroids 
or antibiotics other than the macrolides during enrol- 
ment in the study. The patients had an analysis of 
bronchoalveolar lavage (BAL) fluid before the therapy, 
and the analysis was repeated when the therapy was 
clinically effective. BAL was performed by flexible 
fiberoptic bronchoscopy after local anesthesia of the 
upper airway with 4% lidocaine. The fiberscope was 
wedged into the subsegmental bronchus of the right 
middle lobe, and 150 or 200 mL normal saline was 
instilled in 50-mL aliquots. The BAL fluid was filtered 
through sterile nylon mesh and centrifuged at 1100 
rev/min for 2 min to obtain the cell preparation. The 
cell pellets were later stained with May-Giemsa stain 
and a differential count was performed on 200 cells. 
The lymphocyte subsets were also determined by two- 
color flow cytometric analysis. The remaining fluid was 
centrifuged a t  500 g for 5 min and the supernatant was 
stored at -80°C until used. 
Neutrophil chemotactic activity (NCA) in the 
supernatant was assessed using a 48-well micro- 
chemotaxis chamber, and the levels of interleukin-I p 
(IL-lp) and interleukin-8 (IL-8) or leukotriene B4 
(LTB4) were quantified using enzyme-linked immuno- 
sorbent assay (ELISA) or radioimmunoassay respec- 
tively. Peripheral neutrophil adhesion molecules such as 
LFA-1 and Mac-1 were analyzed by flow cytonietry 
using LFA-la, a monoclonal antibody to the a-chain 
of LFA-1, and Leu15, a monoclonal antibody to the a- 
chain of Mac-I . Finally, in vitro IL-8 production from 
the human monocytic cell line THP-1 was measured 
after incubation with macrolides. 
The effects of niacrolide therapy on respiratory function 
parameters and arterial blood gas analysis are sum- 
marized in Table 1. Treatment significantly iniproved 
Table 1 Change of respiratory function tests and arterial blood gas analysis before and after macrolide therapy 
Erythromycin-treated group Roxithroniym-treated group 
Before After I’ value Before After P value 
vc  (YYI) 71.0k13.3 89.2+ 11.6 P < 0.00 1 86.9k20.2 96.0k21.9 P < 0.001 
FEVl (L) 1 .6k0.8 2.2k0.7 P<0.001 1.8 k 0.9 2.1 f 1.1 I’ <o. 01 
(“A) 64.1 k 14.4 71.5f 13.5 P<0.01 64.3f15.6 69.2f 15.1 P<0.05 
€’a02 (torr) 71.1 k 10.4 81.6k10.1 P<0.001 74.2+ 10.4 84.3 k 10.9 I’ <o. 01 
KV/TLC (“A) 44.9k9.4 35.9k7.8 P<0.001 41.0k7.9 37.21-9.6 NS 
PaC02 (torr) 41.4k 5.3 41.6k2.6 NS 41.3 -t 3.7 39.8k 10.9 NS 
NS=not significant. VC=vital capacity 
FEVl=forced expiration volume in one second. 
Table 2 Neutrophil accumulation and its related factors in bronchoalveolar lavage fluid or peripheral blood before and after 
macrolide therapy 
Before (patients) After (patients) Volunteers (controls) 1’ value 
Neutrophils (%) 62.6f 21.8 21.7 i 22.6 0.8k0.7 P<O.001 
59.9f 23.6 1’<0.001 
NCA’ (“A) 51.4k10.5 30.227.8 27.626.5 P<0.001 
53.1 -t 10.7 P < 0.001 
Interleukin-10 (pg/nL) 40.1 i 5.6 21.8 k2.1 22.6k 1.8 1’<0.05 
37.5k6.3 1’10.01 
344.8k 1 12.4 P<O.OS 
3.5k1.1 P<0.01 
0.70k0.15 P i 0 . 0 5  
Interleukind (pg/mL) 418.8-t 102.0 91.5k28.5 5.5k1.8 I’ .< 0.01 
Lrukotriene Bq (ng/mL) 3.511.1 0.6i-0.3 0.1 f O . O  P<0.001 
Mac-1 expressionb 0.6820.16 0.6020.08 0.45k0.14 P i 0 . 0 5  
a Neutrophil chemotactic activity was expressed as the percentage of the chemotactic response to 10.’ M of N-formyl-methionyl-leucyl- 
phenylalanine (FMLP). 
The ratio of mean channel of fluorescence without stimulation to that with FMLP stiniulation was calculated. 
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the mean value of all parameters, except PaC02 in the 
erythromycin-treated group and RV/TLC and PaC02 
in the roxithromycin-treated group. 
BAL analysis revealed that neutrophils had 
accumulated in the pretreatment lavage fluid, when 
compared with that of healthy volunteers ( P <  0.001; 
Table 2). In addition, the levels of NCA, IL-lp, IL-8 
and LTB4 in BAL fluid of the patients were significantly 
higher than those in healthy volunteers (P<: 0.001 for 
NCA, P<0.05 for IL-lp, P<0.01  for IL-8 and 
P <  0.001 for LTB4 respectively; Table 2). A significant 
correlation was present between the percentage of 
neutrophils and the level of IL-8 in BAL fluid of the 
patients (r = 0.509, P< 0.05). Interestingly, the level of 
IL-lP in the fluid was also significantly related to IL-8, 
with a correlation coefficient of 0.476 (P<0.05). 
Macrolide therapy caused a significant reduction in the 
percentage of neutrophils, the NCA and the mean IL- 
10, IL-8 and LTB4 concentration in BAL fluid of the 
patients (P< 0.001 for neutrophil percentage, P <  0.001 
for NCA, P<0.01  for IL-lp, P<0.05 for IL-8 and 
P< 0.01 for LTB4 respectively; Table 2). Additionally, 
there was a significant correlation between the reduction 
in neutrophil percentage or NCA and the level of LTB4 
( ~ ~ 0 . 7 7 8 ,  P<0.05; and ~ 0 . 8 3 2 ,  P <  0.01). 
The quantitative expression of Mac-1 on peri- 
pheral neutrophils significantly increased compared 
with that in healthy volunteers before the therapy 
(P < 0.05) and significantly decreased after the therapy 
(P<0.05) (Table 2), whereas macrolide had no effect 
in the quantitative expression ofLFA-1 (data not shown). 
For the next step, we evaluated the in vitro effects 
of macrolides on IL-8 production by vitamin D3- 
induced human monocytic cell line THP-1 cells. Upon 
stimulation by 10 ng/mL lipopolysaccharide and 1% 
serum, IL-8 was produced by vitamin D3-treated THP- 
1 cells, together with expression of CD14 molecules, 
while not detected in untreated cells. Macrolides at 
concentration of 10 pg/mL. inhibited IL-8 production 
by vitamin D3-treated THP-1 cells, whereas other 
antibiotics, piperacillin sodium and clindamycin had no 
inhibitory effect. These results suggest that the macro- 
lides with a 14-membered macrocycline ring structure, 
such as erythromycin and roxithromycin might be 
involved in IL-8 release by macrophage-like cells 
through their CD14 molecules. 
The absolute number of lymphocytes in BAL fluid 
was significantly higher in the patients compared with 
that in healthy volunteers ( P <  0.01). Additionally, the 
absolute numbers of memory T-cells and activated 
cytotoxic T-cells were also higher in BAL fluid of the 
patients than in healthy volunteers ( P <  0.001 and 
0.05). These cells were significantly decreased after 
therapy with macrolides ( P <  0.05). 
DISCUSSION 
The accumulation of neutrophils in the airway predicts 
the presence of neutrophil oxidative and proteolytic 
products capable of producing airway damage in the 
lower respiratory tract [5,6]. Low-dose, long-term 
macrolide therapy effected improvement of clinical 
symptoms and laboratory findings and induced the 
reduction of neutrophil accumulation, NCA, IL-1 p, 
IL-8 and LTB4 in the airway, and decreased Mac-1 
expression on peripheral neutrophils. Macrolides also 
inhibited in vitro IL-8 production from THP-1 cells 
stimulated with lipopolysaccharide and serum. These 
results indicate that macrolides may act by reducing 
pulmonary inflammation through reduction of neutro- 
phi1 accumulation, as a consequence of reduced 
chemotactic gradient and cytokine production at the 
inflammatory sites in the lung. Other mechanisms may 
involve reduced neutrophil adhesion molecule in the 
circulation, ultimately by suppression of neutrophil 
oxidative and proteolytic products. 
The present study has also provided evidence for 
T-cell activation in BAL fluid of the patients, and a 
significantly reduced number of activated T-cell was 
observed after macrolide therapy. This observation 
supports the hypothesis that, in addition to neutrophils, 
lymphocytes are important cellular components of 
bronchial inflammation in this disease, and macrolide 
antibiotics may also act as an immunosuppressant to 
inhibit T-cell activation. 
We believe that this could be one reason why 
macrolides are effective in chronic lower respiratory 
tract disease. 
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